Leállítva2. fázis
Safety and Pharmacodynamics of SHR-1707 in Alzheimer's Disease Patients
A legfontosabb adatok
- Ki végzi
- Shanghai Hengrui Pharmaceutical Co., Ltd.
- Hol
- Kína1 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Leállítva
- Fázis
- 2. fázis
- Résztvevők
- 46 fő vett részt
- Kezdés
- 2024. febr. 5.
- Befejezés
- 2026. jan. 30.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
- A vizsgált kezelések
- SHR-1707
- SHR-1707 placebo
- A regiszteradat frissítve
- 2026. május 13.
- Miért állt le
- Based on the adjustment of the sponsor's R\&D strategy, it is decided to terminate this study in advance.
Ki vehet részt
- Életkor
- 50 év – 85 év
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 33 feltétel megnézéseKevesebb
Ki vehet részt
- Age ≥50 and ≤85 on the date of signing the informed consent, males or females
- BMI≥18kg/m2 and ≤32 kg/m2, weight ≥45 kg且≤100 kg at screening or baseline;
- must meet the diagnostic criteria for MCI due to AD or mild AD
- The total score of HAMD-17 should be ≤10 scores at screening
- The score of Hachinski ischemic scale should be ≤4 scores at screening
- amyloid PET scan results from the central laboratory confirmed the presence of pathological changes in AD
- Agreed to test ApoE genotype
- Have a stable caregiver; where symptomatic drugs for AD is used, they must be stable for at least 1 months prior to the screening visit
Ki nem vehet részt
- Patients who had severe trauma or had undergone surgery within 6 months prior to screening, or were scheduled to undergo surgery during the trial
- History of hypoglycemic coma or uncontrolled diabetes 6 months prior to the screening period
- Had unstable or clinically significant cardiovascular disease within 1 year prior to the screening period, had or currently has atrial fibrillation
- Patients with clinically significant systemic immunosuppression due to the persistent effects of immunosuppressive drugs
- According to the investigators, the subjects were suicidal or had committed suicidal behaviour in the six months before the screening period
- A woman who is pregnant, or a woman of childbearing potential whose pregnancy test results are positive, or who is breastfeeding; or has a plan to have a child, unwilling or unable to take effective contraceptive measures within 30 days prior to the screening period or six months after the last use of the investigational drug
- Three months prior to the randomization period or planned to use dual antiplatelet or anticoagulant drugs during the trial
- Received any passive immunotherapy or other long-acting biologics used to prevent or delay cognitive decline within 3 months prior to screening
- Cognitive impairment of subjects due to other medical or neurological factors (other than AD)
- History of stroke or transient ischemic attack, seizures, or other unexplained loss of consciousness within the past year
- Any psychiatric diagnosis that may interfere with the subject's cognitive assessment
- Cannot tolerate MRI or has contraindications to MRI, has significant lesions shown on MRI during screening, or has other conditions that the investigator believes may bring a significant risk to the subject
- History of moderate (3b) or severe renal failure or insufficiency
- Uncontrolled hypertension: systolic blood pressure > 160mmHg and diastolic blood pressure >100mmHg during screening or baseline
- History of malignancy within 5 years prior to screening
- Human immunodeficiency virus antibody (HIV-Ab), treponema pallidum antibody and hepatitis C virus antibody (HCV-Ab) were positive during screening.Hepatitis B active subjects [Hepatitis B virus surface antigen (HBsAg) positive with HBV DNA > upper limit of normal]
- coagulation disorders
- Severe visual or hearing impairment, unable to cooperate with the completion of the scale
- History of drug abuse or addiction
- Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) exceeding 3 times ULN, or total bilirubin exceeding 2 times ULN
- 12-lead ECG showed QTcF >450ms for male and >470ms for female during screening
- Thyroid dysfunction;
- Folic acid or vitamin B12 below the lower limit of normal
- Investigators and relevant staff of the research Centre or others directly involved in programme implementation
- The investigator considers that there are any circumstances that would cause the subject to be unable to complete the study or pose a significant risk to the subject or other factors that would interfere with the subject's ability to complete the study evaluation
Hol van ez a vizsgálat?
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
Evaluate the Safety, Tolerability and Pharmacodynamics of Intravenous Administration of SHR-1707 In Patients with Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease.
A vizsgálat 2 csoportja
- SHR-1707A vizsgált kezelés
- SHR-1707 placeboPlacebo, összehasonlításként
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- A Phase II, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability and Pharmacodynamics of Intravenous Administration of SHR-1707 In Patients With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
- A regiszteradat frissítve
- 2026. május 13.